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Background
Skeletal muscle insulin resistance is an early feature 
during the progression towards type 2 diabetes (T2D) 
and is, in its own right, considered a risk factor for 
cardiovascular disease. While the defects in insulin-
mediated glucose flux have been widely described, the 
global molecular characteristics of insulin resistant 
skeletal muscle have not. Four small gene-chip studies, 
relying on partial coverage of the human transcriptome, 
have attempted to define the global molecular basis of 
insulin resistance in human skeletal muscle [1-4]. While 
pioneering, neither the Yang et al. [4] nor Sreekumar et 
al. [3] studies were genome-wide, both studies suffered 
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from small study populations, and the authors reported 
high false-positive rates. In the third and fourth studies, 
by Mootha et al. [1] and Patti et al. [2], a coordinated 
down-regulation of oxidative phosphorylation related 
(OXPHOS) genes in the skeletal muscle of patients was 
the only change reported and this was proposed to be the 
underlying cause of skeletal muscle insulin resistance 
[5-7]. Indeed, ‘subset’ analysis of a collection of genes (for 
example, 200 to 400) has become a powerful approach to 
detecting coordinated defects in biological pathways in 
vivo, and this method has made important contributions 
to the systems biology field. A separate line of investi-
gation by Petersen et al. [8,9] introduced a magnetic 
resonance spectroscopy approach [10] to study insulin 
resistance in vivo [11]. This method estimates unidirec-
tional ATP synthesis, but it is unclear if it has been 
validated to take into account the multiple assumptions 
that allow net ATP generation to be calculated [12,13]. 
Despite the clear caveats and continuing debate in the 
field [14,15], the concept of an OXPHOS impairment 
[5,16,17] is widely accepted. Nevertheless, a clear expla-
na tion for the general lack of mRNA abundance changes, 
beyond OXPHOS mRNAs, still remains to be explained. 
One thing that it is certainly not due to is the lack of 
sensitivity of gene-chip technology as it readily detects 
high and low abundance RNA molecules under a variety of 
conditions [18-20]. In addition, the general lack of a global 
transcriptional signature has been a consistent finding.
Non-coding RNA has emerged in recent years [21] as 
being of functional importance [22]. In particular, 
microRNAs (miRNAs) are accepted regulators of mamma-
lian cell phenotype [23-25]. miRNAs are approximately 
22-nucleotide post-transcriptional regulators of gene 
product abundance, able to block the translation of 
protein-coding genes [26]. miRNAs regulate development 
and differentiation [27,28] and brain and skeletal muscle 
tissue have the most abundant expression of tissue-
specific miRNA species [29]. miRNAs have been impli-
cated in the regulation of metabolism [27,30] and insulin 
secretion [31] while expression is altered in extreme 
muscle disorders [20,32]. Whether miRNAs are altered 
during the development of diabetes or skeletal muscle 
insulin resistance in humans is unknown, and there are 
still very few studies characterizing miRNA changes in 
vivo, in humans. The molecular rules governing the 
target ing of each miRNA to individual genes have been 
documented [25,33] and help identify which protein 
coding genes are targeted when a single miRNA is modu-
lated in a cell [23,24]. In contrast, multiple changes in 
miRNA abundance can occur in vivo [32], where simul-
taneously up-regulated and down-regulated miRNAs can 
target the same gene but with a range of predicted 
efficacies [25]. To date no study has established the net 
biological impact of multiple miRNA changes in vivo.
In the present study we devised a new strategy for 
predicting which proteins and biological pathways would 
be altered in vivo under such circumstances (Figure S1 in 
Additional file 1). Our approach was built on the in vitro 
molecular rules encompassed by the site-specific context 
score criteria, as these criteria can significantly enrich a 
gene list in genuine targets when a single miRNA is 
studied in a cell-based system [34]. Using three to nine 
times the number of human subjects (n  =  118) as pre-
vious studies [1-4] and a more comprehensive ‘genome-
wide’ RNA profiling strategy (>47,000 mRNA sequences, 
and >500 miRNA sequences), we aimed to identify the 
global molecular nature of skeletal muscle insulin 
resistance in human T2D and provide new bioinformatic 
and protein level validation for our conclusions.
Methods
We recruited 118 subjects for the study (Table 1) and the 
degree of insulin resistance was verified by applying the 
World Health Organization diagnostic criteria for dia-
betes [35]. Exclusion criteria were treatment with insulin, 
recent or ongoing infection, history of malignant disease 
or treatment with anti-inflammatory drugs. The cohort 
consisted of approximately 65% male and 35% female 
subjects. Participants were given both oral and written 
information about the experimental procedures before 
giving their written, informed consent. The study was 
approved by the Ethical Committee of Copenhagen and 
Frederiksberg Communities, Denmark (j.nr (KF) 01-141/04), 
and performed according to the Declaration of Helsinki.
Clinical evaluation protocol
Participants reported between 8 and 10 am to the 
laboratory after an overnight fast. Subjects did not take 
their usual medication for 24 hours preceding the exami-
nation, and T2D subjects did not take hypo glycemic 
Table 1. Characteristics of the 3 subject populations in the 
study
 T2D (n = 45) IGT (n = 26) NGT (n = 47)
Age 54.8 ± 10.2 56.4 ± 10.7 51.3 ± 10.7
BMI 31.4 ± 6.2 30.9 ± 6.1 31.1 ± 7.2
VO2max 26.9 ± 8.4 28.2 ± 9.7 29.5 ± 10.5
Fasting glucose 9.8 ± 4.4* 5.9 ± 0.5† 5.0 ± 0.4
Fasting insulin 91.2± 8.9† 88.2± 13.5‡ 56.6± 8.3
HOMA1log 0.67± 0.07* 0.46± 0.05* 0.20± 0.05
2-h glucose (OGTT) 17.9 ± 5.5* 7.4 ± 2.4† 5.5 ± 1.2
HbA1c 7.4 ± 1.8* 5.8 ± 0.3† 5.5 ± 0.2
Data are mean ± standard deviation. BMI, body mass index; 
VO
2max
, ml/kg/minute; Fasting glucose and 2-h glucose tolerance is mmol/L; 
HbA1c is percentage glycosylated hemoglobin. *P < 0.001 when compared with 
either NGT or IGT; †P < 0.01 when compared with the NGT group; ‡P = 0.07 when 
compared with the NGT group. OGTT, oral glucose tolerance test.
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medicine for 1 week prior to examination. Note that the 
correlation between fasting glucose and hbA1c remained 
high (R2 = 0.71; Additional file 2), indicating that short-
term glucose homeostasis did not appear greatly 
disrupted by the 1-week drug withdrawal. Body mass and 
height were determined for body mass index (BMI) 
calculations. The subjects performed an oral glucose 
tolerance test and an aerobic capacity test. Peak aerobic 
capacity was determined by the Åstrand-Ryhming indirect 
test of maximal oxygen uptake (VO2max) [36].
Blood analyses and oral glucose tolerance test
Blood samples were drawn before and 1 and 2 hours after 
drinking 500  ml of water containing 75  g of dissolved 
glucose. The World Health Organization diagnostic 
criteria were applied, as were calculations of insulin 
resistance (homeostatic model assessment (HOMA)). 
Plasma was obtained by drawing blood samples into glass 
tubes containing EDTA and serum was obtained by 
drawing blood into glass tubes containing a clot-inducing 
plug. The tubes were immediately spun at 3,500  g for 
15 minutes at 4°C and the supernatant was isolated and 
stored at -20°C until analyses were performed. Plasma 
glucose was determined using an automatic analyzer 
(Cobas Fara, Roche, France). All samples and standards 
were run as duplicates and the mean of the duplicates 
was used in the statistical analyses.
Muscle tissue biopsies
Muscle biopsies were obtained from the vastus lateralis 
using the percutaneous needle method with suction [37]. 
Prior to each biopsy, local anesthetic (lidocaine, 20 mg ml-1; 
SAD, Denmark) was applied to the skin and superficial 
fascia of the biopsy site. Visible blood contamination was 
carefully removed and all biopsies were frozen in liquid 
nitrogen and subsequently stored at -80°C until further 
analysis. RNA extraction was carried out using TRIzol 
(Invitrogen, Carlsbad, CA, USA) and a motor-driven 
homogenizer (Polytron, Kinematica, Newark, NJ, USA) as 
described [38].
Affymetrix microarray
Hybridization, washing, staining and scanning of the 
arrays were performed according to manufacturer’s 
instruc tions (Affymetrix, Inc. [39]). We utilized the 
Affymetrix U133+2 array platform and 15  µg of cRNA 
was loaded onto each chip. All array data were normal-
ized using the Microarray Suite version 5.0 (MAS 5.0) 
algorithm to a global scaling intensity of 100. Arrays were 
examined using hierarchical clustering to identify outliers 
prior to statistical analysis, in addition to the standard 
quality assessments, including scaling factors and NUSE 
plot. No array included in this analysis failed these 
standard quality assurance procedures. We relied on 
several statistical approaches to analyze the data with and 
without pre-filtering of gene lists. We utilized custom chip 
definition files (CDFs) [40] to improve the anno ta tion 
precision [41]. Using the MAS 5.0-generated present-
absent calls improves the sensitivity of the differential gene 
expression analysis [42] as it increases the statistical power 
of the analysis. We chose to remove probe sets that were 
declared ‘absent’ across all chips in the study. The micro-
array data were subjected to global normalization using 
the robust multi-array average expression measure (RMA) 
in the Bioconductor suite [43] and analyses were compared 
in parallel with MAS 5.0-based normalization, following 
the negative result (see below) with the MAS 5.0 data. The 
CEL files have been deposited at the Gene Expression 
Omnibus under reference number [GEO:GSE18732] and 
patient pheno type data have also been made available at 
the same location and with this manuscript.
miRNA microarrays
Total RNA was pooled from groups of subjects with 
similar clinical profiles from the larger cohort. This was 
done to generate sufficient RNA for labeling and the 
average clinical profile of the subjects that contributed to 
the miRNA analysis can be found in Table  S1 in 
Additional file  1. Each sub-pool was >2  μg and 4 inde-
pendent miRNA profiles per clinical subgroup were 
created (resulting in a total of 16 independent miRNA 
determinations per clinical condition). The microarrays 
were miRCURY™ v10.0 LNA miRNA array from Exiqon 
(Vedbaek, Denmark). The Exiqon probe set consists of 
1,700 custom made capture probes that are enhanced 
using locked nucleic acid (LNA) technology, which is 
claimed to normalize the Tm of the capture probes, as 
insertion of one LNA molecule into the capture probes 
increases the Tm by 2 to 8°C. Total RNA (2  μg) was 
labeled with Hy3 dye according to the manufacturer’s 
protocol using the labeling kit from Exiqon. For the 
labeling reaction, RNA was incubated with the Hy3 dye, 
labeling enzyme and spike-in miRNAs, in a total volume 
of 12.5 μl, for 1 hour at 16°C. The enzyme was then heat-
inactivated at 65°C for 15 minutes. The samples were 
incubated at 95°C for 2 minutes, protected from light. A 
total of 32.5 μl of hybridization buffer was added to make 
up the volume required by the hybridization station. The 
samples were briefly spun down and filtered through a 
0.45-micron durapore filter (Millipore, Billerica, USA). 
Samples were then loaded onto the MAUI (BioMicro 
Inc., Salt Lake City, UT, USA) hybridization station. The 
arrays were incubated at 56°C for 16 hours, then washed 
briefly in 60°C using buffer A, rinsed in buffer B, followed 
by a 2-minute wash in buffer B and a 2-minute wash in 
buffer C. The arrays were spun for 5 minutes at 1,000 rpm 
followed by immediate scanning using a GenePix 4200A 
microarray scanner. Data were analyzed using GenePix 
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Pro 6® software. Following quantile normalization of the 
entire chip, the distribution of intensities was plotted for 
all of the human annotated miRNA probes and this was 
compared with background signal intensities, with a 
cutoff of 400 units being taken as an expressed miRNA 
(total of 171 human miRNAs). Differential expression 
was determined using the significance of microarray 
analysis (SAM) approach and miRNAs with a false 
discovery rate (FDR) of 10% or better and modulated by 
>30% were selected for further validation studies. Quan-
tile normalized raw data can be found in Additional file 2. 
Changes were verified using the Applied Biosystems 
TaqMan assays (Applied Biosystems, Foster City, CA, 
USA) on individual patient samples (Table S1 in Additional 
file 1; n = 10 for each patient group) and pooled RNA for 
Northern blots (where stated).
Real time quantitative PCR detection of mature miRNAs in 
skeletal muscle
Individual muscle RNA samples from 30 subjects 
(Table S1 in Additional file 1) were used for detection of 
individual miRNA expression. Subjects were matched to 
have identical age, BMI and maximal oxygen uptake 
(VO2max); note that we profiled only non-obese subjects 
for resource reasons. The Taqman® MicroRNA assay 
(Applied Biosystems), which detects mature miRNA, was 
used to measure miR-1 (Cat#4373161), miR-133a 
(Cat#4373142), miR-133b (Cat# 4373172) and miR-206 
(Cat#4373092). The assay relies on a miRNA-specific 
looped primer for the reverse transcription (RT) reaction, 
which extends the mature miRNA sequence and enables 
detection in the subsequent Taqman assay. It is possible 
for the RT step to amplify the closely related pre-miRNA 
sequence. However, in competition with a more efficiently 
amplified, primer extended mature miRNA, an insigni-
ficant contribution from the pre-miRNA to the real time 
PCR signal is expected (approximately 1 to 5%) [44,45].
For each miRNA RT-PCR reaction, 5 ng of total RNA 
was reverse transcribed using the TaqMan® MicroRNA 
Reverse Transcription Kit (Applied Biosystems, PN4366597) 
and miRNA-specific primers. For quantitative real-time 
PCR (qPCR) the TaqMan® 2X Universal PCR Master Mix 
No AmpErase® UNG was used (Applied Biosystems, 
PN4324020). The samples were run on a 7900 Fast Real-
Time PCR System (Applied Biosystems) on the 9600 
emulation mode in triplicates of 10  µl per well. The 
miRNA expression levels were normalized to the small 
nuclear RNA RNU48 (Cat#4373383), which appears not 
to vary between subject samples for human skeletal 
muscle (using 18S as a comparator for RNU48). All 
reactions were run single-plex in triplicate and quantified 
using the ΔCt method. Data are analyzed using ANOVA 
to compare differences in ΔCt values between the three 
groups followed by a post hoc t-test where appropriate to 
identify specific group differences. For all analyses P < 0.05 
was considered significant. Statistical calcula tions were 
performed using SPSS (SPSS Inc, Chicago, IL, USA) or 
Sigmastat (Systat Software Inc, San Jose, CA, USA).
Detection of pri-miRNA expression using SYBR green qPCR
To determine if pri-miRNA transcript abundance differs 
across the presumed polycistronic mir-1/mir-133a pri-
miRNA, we utilized qPCR. Reverse transcription was 
performed on 1  µg RNA in a reaction volume of 40  µl 
using the high capacity cDNA reverse transcription kit 
(Applied Biosystems) and random hexamers. The RT 
reaction was run at 25ºC for 10 minutes, 37ºC for 
120  minutes, and 85ºC for 5 s. SYBR green reagents 
(Applied Biosystems) were used for detection of the pri-
miRNA transcripts. Primers were designed to amplify 
the genomic region near the pre-miRNA hairpin to 
determine whether ‘neighboring’ pri-miRNAs are expressed 
in a similar manner. Primer sequences are listed in 
Table  S2 in Additional file 1. Primer efficiency was 
established by plotting a standard curve of Ct values from 
serial dilutions of cDNA and these were similar in all 
cases. Each qPCR reaction was prepared using 6 µl SYBR 
green mastermix, 4.6 µl nuclease-free H2O, 30 nM forward 
primer, 30 nM reverse primer and 1.2 µl of a 1:10 cDNA 
dilution in a total volume of 10 µl. The PCR reaction was 
run on an Applied Biosystems 7900 Fast Real-Time PCR 
system in standard mode, 10 minutes at 95ºC, then 45 
cycles consisting of 15 s at 95ºC and 60 s at 60ºC. Ct 
values for triplicates were averaged and ΔCt values 
computed using 18S as the control.
Northern blot to detect pre- and mature miRNA}
To enable detection by Northern blotting, RNA was 
pooled from each of the three groups above to provide 
independent pools of 10 µg of total RNA. An 
oligonucleotide was synthesized to probe for miR-133a/b 
(5’-AGCUGGUUGAAGGGGACCAAA-3’). A small RNA 
blot was prepared using a 15% denaturing gel, consisting 
of 15  ml SequaFlowGel sequencing system concentrate, 
7.5  ml SequaFlowGel diluent, 2.5  ml 10× MOPS buffer, 
250 µl 10% ammonium persulfate (Sigma, Poole, Dorset, 
UK) and 25  µl tetramethylethylenediamine. RNA was 
dissolved in 2× formamide loading dye, incubated at 95ºC 
for 2 minutes and loaded onto the gel along with Decade 
Marker (AM7778, Applied Biosystems). The gel was pre-
heated and then run at 100V for 3 hours using the WB 
system (Invitrogen) with 1× MOPS/NaOH (20 mM, pH 
7.0) running buffer. The RNA was transferred to a 
HybondN neutral membrane (Amersham Biosciences, 
Little Chalforn, Bucks, UK) by applying a current of 
400  mA for 1 to 1.5 hours. For chemical cross-linking 
[46] the membrane was incubated at 55ºC for 2 hours in a 
cross-linking solution consisting of 9 ml RNase free water, 
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245 µl 1-methylimidazole, 300µl 1 M HCl and 0.753 g 
EDC (N-Ethyl-N’-(3-dimethylaminopropyl)carbodiimide 
hydrochloride). After membrane incubation at 37ºC for 
1  hour in a pre-hybridization mix (12.5 ml formamide, 
6.25 ml SSPE (20×), 1.25 ml Denhardt (100×), 1.25 ml 
10% SDS and 500 µl herring sperm (hs)DNA (2 mg/ml)) 
hybridization occurred overnight in a solution of 1 µl 
50  µM oligo, 11 µl nuclease-free water, 2 µl 10× buffer, 
2 µl RNase inhibitor, 2 µl T4 PNK (polynucleotide kinase) 
and 2 µl 32P-j-ATP that had been incubated at 37ºC for 
1 hour and filtered through a G-25 column. The membrane 
was then washed twice in 2× SSC and 0.1% SDS for 
1.5 hour at 65ºC and hybridization was detected by Kodak 
photographic film. The membrane was subsequently 
stripped and re-probed for tRNA as a loading control.
miRNA knockdown and western blot analysis in C2C12 
myoblasts
C2C12 cells were seeded at 50% confluency in Dulbecco’s 
modified Eagle’s medium (DMEM) and 10% fetal calf 
serum (FCS). Before transfection cells were transferred to 
the serum and antibiotic free medium Optimem (Invitro-
gen), and transfected with 100 nM LNA miRNA inhibi-
tors or scrambled oligo (Exiqon) with Oligofectamine 
(Invitrogen) following the manufacturer’s protocol. Four 
hours after the transfection, FCS was added back to a 
final concentration of 8%. After 48 hours the cells were 
lysed, and RNA and protein were isolated and retained 
for further analysis. Cells were lysed by boiling in 
Laemmli buffer for 5 minutes. Insoluble material was 
removed by centrifugation and protein content quantified 
using the BCA reagent (Pierce, Little Chalforn, Bucks, 
UK). Proteins were size fractionated by SDS-PAGE using 
a 4 to 12% gradient bis-Tris NuPage gel (Invitrogen) and 
transferred onto a nitrocellulose membrane (Whatman, 
Little Chalforn, Bucks, UK). The efficacy of the transfer 
was examined by Ponceau Red staining of the membrane. 
The membrane was blocked by incubation at room 
tempera ture with a solution of 5% skimmed milk in Tris-
buffered saline (TBS), 0.2% Tween, 0.05% Triton X100 
(TBST) or 5% bovine serum albumin (BSA) in TBST. 
Incubation with primary antibody anti-PTBP1 (Polypyri-
midine tract-binding protein 1; Proteintech Group Inc. 
(Chicago, Illinois, USA) at 1:1,000 in 5% skimmed milk/
TBST or anti-CDC42 (Cell Signaling Technology, 
Danvers, MA, USA) at 1:1,000 in 5% BSA/TBST) took 
place overnight at 4ºC. Blots were washed and incubated 
with an anti-rabbit IgG horse radish peroxidase- 
conjugated antibody (1:5,000; Cell Signaling Technology) 
for 1 hour at room temperature. Specific signal was 
detected using the ECL reagent (GE Healthcare, Little 
Chalforn, Bucks, UK) and exposure on Kodak BioLight 
film. An image of the Ponceau membrane and each blot 
were analyzed using the ImageJ software (NIH). The area 
under the curve for each blot signal was corrected for 
protein loading using the area under the curve from the 
Ponceau signal. These loading corrected signals were 
then scaled to the signal for the cells transfected with 
scrambled sequence and percentage changes in signal 
were calculated. A minimum of two independent cell 
transfections were carried out.
Muscle tissue western blot analysis
Human muscle samples were homogenized (n = 13) 
using a Tissue-lyser (Qiagen, Crawley, West Sussex, UK) 
in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EGTA, 
1 mM EDTA, 0.25% NaDeoxycholate, 1% Triton X-100. 
Phosphatase inhibitor cocktail 1 and 2 (Sigma Aldrich, 
Poole, Dorset, UK) and protease inhibitor complete mini 
(Roche, Welwyn Garden City, Hertfordshire, UK) was 
added to the buffer immediately before homogenization. 
Following homogenization, protein lysates were centri-
fuged at maximum speed for 1 hour at 4°C and the pellet 
was discarded. Protein concentration was measured 
using a Bio-Rad protein assay. Samples were diluted in 5× 
Laemmli buffer and boiled for 2 minutes before 
subsequent loading of 25 µg onto a 4 to 12% gradient bis-
Tris NuPage gel (Invitrogen). The gel was run for 
120 minutes at 125V and protein was transferred onto a 
PVDF membrane using a semi-dry blotting system for 
2 hours at 20V (Invitrogen). The membrane was blocked 
for 1 hour at room temperature in 5% skimmed milk. 
Incubation with primary antibody took place overnight 
at 4ºC. Antibody dilutions were: anti-PTBP1 at 1:4,000 in 
5% skimmed milk/TBST; anti-CDC42 at 1:4,000 in 5% 
BSA/TBST; anti-HOXA3 (Abnova, Walnut, CA, USA) at 
1:2,000 in 5% milk; anti-HOXC8 (Abnova) 1:1,000 in 5% 
milk; anti-BIM at 1:2,000 in 5% BSA; and anti-BDNF 
(Brain-derived neurotrophic factor; Santa Cruz, Santa 
Cruz, CA, USA) at 1:200 in 0.25% BSA. Blots were 
washed and incubated with anti-rabbit or anti-mouse IgG 
horse radish peroxidase-conjugated antibody (1:2,000; Cell 
Signaling Technology) for 1 hour at room temperature. 
The signal was detected using Supersignal West Femto 
Luminal/Enhancer Solution (Thermo Scientific, Waltham, 
MA, USA) and subsequent exposure in a charge-coupled 
device camera (Bio-Rad, Hemel Hempstead, Hertfordshire, 
UK). Following exposure, blots were briefly rinsed in TBST 
and then incubated in 0.5% Reactive Brown (Sigma 
Aldrich) for 15  minutes. Blots were analyzed and 
quantified using ImageQuant (Amersham, Little Chalfont, 
Bucks, UK) software, with the reactive brown image as a 
control for equal loading and transfer.
Human muscle satellite cell isolation, proliferation and 
differentiation
Satellite cells were isolated from vastus lateralis muscle 
biopsies as previously described [47]. Briefly, following 
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removal of fat and connective tissue, the biopsy was 
digested in a 10 ml buffer containing trypsin and collage-
nase II for 5+10 minutes. To minimize fibroblast 
contamination, cells were pre-seeded in a culture dish for 
3 hours in F10/HAM, 20% FBS, 1% penicillin/strepto-
mycin (PS), 1% Fungizone. Unattached cells were then 
removed and seeded into a culture flask, pre-coated with 
matrigel (BD Biosciences, San Jose, CA, USA). Following 
4 days of incubation, the cell culture medium was 
changed and then every second day thereafter. Cell 
cultures were expanded and then seeded for proliferation 
or differentiation. For proliferation, satellite cells were 
seeded into culture dishes pre-coated with matrigel (BD 
Biosciences). Cell culture medium was changed to 
DMEM low glucose, 10% FBS, 1% PS. Cells were allowed 
to become 75% confluent and then harvested in cell lysis 
buffer (Cell Signaling Technology). For differentiation, 
the cell culture medium was changed to DMEM low 
glucose, 10% FBS, 1% PS and cells were allowed to 
become completely confluent. When the satellite cells 
started to change morphology and line-up, the medium 
was changed to DMEM high glucose, 2% horse serum, 
1% PS. At day 5 on low serum, myotubes were formed 
and harvested in cell lysis buffer (Cell Signaling 
Technology).
miRNA target prediction and Gene Ontology analysis
The binding of miRNA to target mRNA occurs between 
the ‘seed’ region of the miRNA (nucleotides 2 to 7 of the 
5’ end of the mature miRNA) and the 3’ untranslated 
region of the mRNA. Gene lists of predicted targets for 
each modulated miRNA were obtained using TargetScan 
4.2 [48]. Several groups have used microarray data to 
examine the expression changes when a single miRNA 
changes, and we used the mean absolute expression 
approach described recently by Arora and Simpson [49] 
and also the tissue-centric approach described by Sood et 
al. [50] to determine whether we could detect shifts in the 
average expression of mRNA targets of the muscle-specific 
miRNAs (miR-1, miR-133a/b and miR-206, collectively 
known as ‘myomirs’) in human skeletal muscle. We found 
no evidence of systematic mRNA changes.
We thus set out to generate a new method of predicting 
which genes should be altered in the face of multiple 
changes in miRNA concentration. The development of 
ranking procedure is described in detail within the results 
section. We used Gene Ontology analysis [51] to obtain 
an overview of the functions of predicted gene lists and 
select protein targets for further evaluation in cell culture 
and tissue samples. For Gene Ontology analysis we 
filtered predicted gene target lists using tissue-specific 
gene expression profiles derived from U133a+2 Affy-
metrix chip data (n = 118). We also utilized the global 
muscle transcriptome as the background RNA expression 
data set, as misleading ontological enrichment P-values 
are yielded when a generic (genome-wide) reference data 
set is utilized.
Results
Global transcription in skeletal muscle is unaltered in type 
2 diabetes
Simple hierarchical clustering and scatter plots of ‘gene 
sets’ were used to explore the dataset. As can be seen 
from Figure S2 in Additional file 1 global clustering by 
subject (n = 118) resulted in a plot that distributed healthy 
controls (normal glucose tolerance (NGT), black-bar), 
impaired glucose tolerance (IGT, yellow-bar) and patients 
(T2D, red-bar) across the data set, with no obvious 
grouping of subjects and was not dependent on the 
normalization method (data not shown). The Affymetrix 
data were then analyzed using SAM [52] and limma in R 
[53]. No significant differences in individual gene expres-
sion were found between the subject groups with either 
method. To further test this conclusion, we utilized a 
quantitative correlation analysis approach whereby each 
individual gene’s expression was related to fasting glucose 
and fasting insulin. This correlation analysis is a logical 
approach, as the threshold when a patient is diagnosed 
with T2D is pragmatic, driven by categorization of risk to 
aid medical treatment. Quantitative SAM analysis 
produces a FDR for genes that positively and negatively 
correlated with these two markers of clinical status. A 
modest number of genes (approximately 50) were found 
to correlate significantly with fasting glucose (FDR = 5%) 
and even fewer with insulin levels (approximately 10). 
However, the correlation coefficients were very modest; 
gene expression values covered approximately 90% of the 
range for insulin or glucose and thus can be deemed of 
limited biological significance (limma based analysis 
found even fewer genes). Thus, gene chip analysis 
indicates that T2D and muscle insulin resistance are not 
associated with global changes in mRNA abundance, 
despite the sensitivity of the technology [18-20]. We ran 
two smaller human skeletal muscle studies [20] at the 
same core-lab and both yielded substantial (1,000 to 
3,000) differential expression using the same methods 
and staff. Given this, and the larger sample size of this 
diabetes study, and the substantial difference in insulin 
resistance (Table 1), the lack of global mRNA changes in 
T2D appears convincing.
Mitochondrial related transcript abundance is not 
associated with insulin resistance
Another approach to improve statistical power is to 
select a small subset of genes on the gene chip for 
analysis. For example, on the Affymetrix gene chip, >400 
genes are annotated as carrying out mitochondrial 
related functions; this list of genes has been called the 
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‘OXPHOS’ gene set [1]. We plotted the expression of the 
OXPHOS gene set in NGT versus T2D subjects 
(Figure 1a) and the OXPHOS mRNAs fell on the line of 
equality, indicating no differential expression. We then 
investigated if a physiological parameter may explain the 
difference between our study and that of Mootha. We did 
this by creating a subgroup of patients (Table S3 in 
Additional file 1) where the control subjects (n = 14) had 
a lower BMI and a higher aerobic capacity than the T2D 
subjects (n = 17) - that is, less well matched - similar to 
the Mootha et al. study. Again, we found no alteration in 
OXPHOS gene expression (Figure  1b). Furthermore, 
there is no correlation between OXPHOS gene expres-
sion and HOMA1 (Figure 1c) or HOMA2 expression, or 
Figure 1. OXPHOS gene expression and relationship to disease status. (a) Plot of median intensity of OXPHOS probes (red circles) for NGT 
(n = 47) versus T2D (DM; n = 45) on the background of absent filtered probesets (black circles). The insert shows the mean expression of OXPHOS 
probesets (± standard error of the mean). (b) Plot of median intensity of OXPHOS probes (red circles) for NGT (n = 14) versus T2D (n = 17) on the 
background of absent filtered probesets (black circles). These subjects have the same physiological characteristics as those in the Mootha et al. 
study [1]. The insert shows the mean expression of OXPHOS probesets (±standard error of the mean). (c) Correlation plot for HOMA2 insulin 
resistance (IR) and MAS 5.0 normalized expression values for the OXPHOS probe sets. Each point represents the median expression for an OXPHOS 
probe set after filtering the Affymetrix data as described above. The subject groups are represented by colored points: black = normal glucose 
tolerance; green = impaired glucose tolerance; red = type 2 diabetic. The regression line is shown in black along with the R squared value for 
goodness of fit and the P-value indicating significance of the relationship. (d) The linear correlation between 2 hour blood glucose (during oral 
glucose tolerance test) and PGC-1α expression (n = 118) in skeletal muscle of subjects across the clinical groups NGT (black-dots), IGT (green-dots) 
and T2D (red-dots) derived from the Affymetrix probe set. The regression line is shown in black along with the R squared value for goodness of fit 
and the P-value indicating significance of the relationship.
(a) (b)
(c) (d)
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between peroxisome proliferator-activated receptor-gamma 
coactivator-1α (PGC-1α) and plasma glucose concen-
tration (Figure 1d).
We then used a more powerful statistical method, gene 
set enrichment analysis (GSEA), using both the original 
[1] and adapted versions of GSEA and their respective 
‘gene sets’ [54]. While we could reproduce the results of 
Mootha et al. using their clinical samples and both 
methods, when we examined our larger data set, no gene 
set was enriched (using the original and latest C2.all.v2.5 
list). OXPHOS related gene sets (six such lists are 
included with the program) appeared distributed across 
the list of enriched genes in control subjects (ranked at 
positions 8, 14, 57, 66, 370 and 391) and none were statis-
tically significant. Finally, we ran GSEA on the subgroup 
that re-created the patient characteristics of the Mootha 
et al. study and found that the ‘Mootha_VOXPHOS’ 
gene-set had a FDR of 96%. The only remaining 
distinguishing feature we are aware of, between these 
studies, is the 3 hour pharmacological insulin infusion 
protocol utilized by Mootha et al. prior to biopsy sampling 
(see Discussion). Thus, based on analysis of the largest 
available human muscle T2D array data set, we can 
conclude that there are no robust changes in protein-
coding mRNAs in the skeletal muscle of diabetes patients 
(although this does not rule out subtle changes in splice 
variants). The analysis suggests that a post-transcriptional 
mechanism should exist to regulate the development of 
insulin resistance in T2D patients, so we tested the hypo-
the sis that altered miRNA expression occurs and in a 
manner that relates to the development of insulin resistance.
Analysis of global diabetes-induced changes in skeletal 
muscle miRNA expression
We detected approximately 170 human miRNAs in 
skeletal muscle tissue, consistent with muscle expressing 
a large number of miRNA species. Twenty-nine were 
significantly up-regulated by >1.3-fold (FDR <10%), while 
33 were down-regulated by >1.3-fold (FDR <10%) in T2D 
(Additional file 2). Taking the miRNAs that were differen-
tially expressed in patients with T2D, we then plotted 
their expression and included the impaired glucose 
tolerance samples (Figure 2a). It was clearly evident that 
approximately 15% of up-regulated and approximately 
15% of down-regulated miRNAs were altered early in the 
disease process, while many changed progressively and a 
substantial minority were found to be altered only once 
the patients had diabetes (Figure 2a). By cross-referencing 
[18] gene chip data sets we identified that 11 from 61 
miRNAs demonstrate a pattern of change in expression 
(Figure 2b) that was the exact opposite of that observed 
during muscle differentiation [55]. As far as we are aware 
the only study of myocyte differentiation, in the context 
of diabetes, derives from streptozotocin-diabetic rats, 
where primary muscle from diabetic animals fails to 
robustly fuse to form multinucleated myotubes in vitro 
[56]. Since we observed an inverse relationship between 
‘muscle development’ miRNAs and changes in diabetes, 
we further investigated the reason for altered expression 
of the muscle specific miRNAs.
Muscle-specific mature miRNAs are down-regulated in 
type 2 diabetes
Mature myomirs were measured in skeletal muscle 
biopsies from three different groups (Table S1 in Addi-
tional file 1; T2D, n = 10; IGT, n = 10; and NGT, n = 10). 
ANOVA indicated that miR-133a (F = 11.8, P < 0.0001) 
was significantly different between the three groups, 
miR-206 expression more modestly altered (F  =  4.5, 
P  =  0.02) and miR-1 and miR-133b were unchanged 
(Figure  2c). Northern analysis was used to document 
differ ences in precursor miR-133 and mature miR-133 
abundance. The Northern probe detects both miR-133a 
and miR-133b due to sequence similarity. The steady 
state level of pre-miR-133 was very low in human skeletal 
muscle compared with the signal from the mature 
miR-133a/b expression transcript (Figure S3 in 
Additional file 1). This confirms that along with the much 
lower (>100 times) amplification efficiency [45], miR-133 
pre-miRNA cannot contribute to the TaqMan signal.
Skeletal muscle miR-133a expression was reduced by 
five-fold in T2D (P < 0.001). A clear stepwise reduction in 
mature miR-133a expression was observed across the 
three clinical groups. We found that expression of 
miR-133a was associated with fasting glucose and 2 hour 
glucose tolerance data (R2 = 0.37, P < 0.001), with higher 
fasting glucose levels associated with lower miR-133a 
expression (Figure 2d). In addition, miR-133a expression 
was significantly associated with HbA1c, an indicator of 
long-term glucose homeostasis (R2 = 0.29, P < 0.01) and 
also correlated with HOMA1 (R2 = 0.15, P = 0.04). A total 
of six correlations were carried out and the P-values are 
unadjusted. Subsequently, we checked miR-206, which 
associated more modestly with these clinical parameters, 
and miR-1, which did not associate with any of these clinical 
parameters. Thus, we found that altered miR-133a 
expression modestly related to important clinical para-
meters. We then investigated if the altered steady-state level 
of mature miR-133a was a consequence of failure to produce 
the primary RNA transcript in the nucleus (Figure S3B in 
Additional file 1). As the pri-miRNA abundances were 
unchanged, altered processing or degradation appears 
responsible for the loss in selective myomir expression 
rather than altered transcription.
Detection of miRNA-133a target protein in vitro and in vivo
There was no change in the mRNA expression of genes 
that contained myomir target sites (data not shown); 
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thus, miR-133a may only target protein translation rather 
than mRNA cleavage. Using western blotting, we exam-
ined if loss of myomir expression could detectably 
increase protein targets in a muscle cell model. CDC42 
and PTBP1 were selected for study because they ranked 
highly as targets of miR-133/miR-206 in the TargetScan 
database and both proteins are relevant for muscle cell 
differentiation and metabolism [57,58]. Interestingly, 
reduction in miR-133a using an antagomir (Figure S4A in 
Additional file 1) had an indirect effect on the other 
myomirs, such that miR-133b (expected due to sequence 
similarity) and miR-206 (unexpected) were substantially 
reduced. This altered expression pattern of mature 
myomirs was not associated with substantial changes in 
pri-miRNA expression (Figure S4B in Additional file 1), 
suggesting some degree of physiological feedback on 
miRNA maturation during the use of a so-called ‘selective’ 
antagomir [59]. Western analysis of CDC42 and PTBP1 
demonstrated expected increases (approxi mately 37% 
and 20%, respectively) in protein expression following 
antagomir treatment (Figure S4C in Additional file 1), 
confirming the suitability of antibodies against them for 
in vivo profiling.
In contrast, analysis of CDC42 and PTBP1 proteins in 
muscle tissue provided no evidence that these targets 
were altered in vivo (n = 7 to 8 subjects per group; 
Figure 2. miRNA expression profile changes in T2D compared with control subjects using the Exiqon chip platform and TaqMan 
confirmation (FDR <10%). (a) Data are plotted to show the pattern of change of these significantly up-/down-regulated miRNA. Black lines 
represent those miRNA that increase/decrease progressively with IGT and T2D (DM), green lines represent miRNAs that are increased/decreased 
with IGT and then revert with T2D, while orange lines show miRNAs increased/decreased only in the T2D state. (b) miRNAs that show the 
expression profile during myocyte differentiation (cell data derived from Chen et al. [55]) is the opposite pattern to that observed in the muscle of 
patients with T2D (green = down-regulated probe sets, red = up-regulated probe sets; the color range is from -3-fold to +3-fold change). MG refers 
to the data produced by Chen et al. during myogenesis. (c) Expression level of miR-1, miR-133a, miR-133b and miR-206 in muscle biopsies from 
healthy individuals (NGT, n = 10, white bars), individuals with impaired glucose tolerance (IGT, n = 10, grey bars) and individuals with type 2 diabetes 
(T2D, n = 10, black bars). miR-133a (P < 0.001) and miR-206 (P = 0.04) were significantly reduced in T2D patients when compared with expression 
levels in healthy controls. Data are expressed as fold change from NGT and shown as mean ± standard error. **P < 0.001, *P < 0.05. (d) Expression 
level of miR-133a in muscle versus indices of glucose homeostasis in subjects with and without T2D. Expression of miR-133a is positively correlated 
with fasting glucose, R2 = 0.41 (P < 0.001, n = 30). Data are shown as ΔCt levels normalized to RNU48 and plotted versus fasting glucose levels (mmol/L).
(a) (b)
(c) (d)
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Figure  S4D in Additional file 1). Indeed, two recent 
studies documenting the first global analysis of the 
relationship between miRNA and the proteome [23,24] 
found that altered expression of single miRNAs typically 
had a modest impact on individual protein expression, 
suggesting to us that the collective changes in many 
miRNAs may be the most biologically interesting para-
meter to consider. Thus, we hypothesized that the most 
likely scenario is that groups of miRNAs work co-
operatively in vivo, and that physiological regulation of a 
single muscle protein by a single miRNA may be a rather 
rare occurrence [60]. It is with this in mind that we set 
about developing a new ranking system (Figure S1 in 
Additional file 1) for altered tissue miRNA expression to 
help define the biochemical consequences of the altered 
expression of the approximately 60 miRNAs in T2D. 
Interestingly, our new analysis procedure subsequently 
identified CDC42 and PTBP1 as being equally targeted 
by both up- and down-regulated miRNAs (Additional 
file 2); thus, CDC42 and PTBP1 should not be altered in 
vivo by diabetes (as we demonstrated by western blotting 
prior to developing our ranking metric).
A novel weighted context score ranking analysis of global 
changes in diabetes-induced changes in miRNA expression
Even a modest reduction in protein content can, if within 
a single canonical pathway, have a strong impact on 
physiological function. With this in mind, we hypothe-
sized that the main biological consequence of multiple in 
vivo miRNA changes may reflect the collective targeting 
of multiple members of selected signaling pathways. The 
collective ‘activity’ must reflect the observation that both 
up-regulated and down-regulated miRNA can target the 
same genes such that the biological impact cannot be 
assessed using single miRNA-target associations. We 
devised a ranking system using the conserved target site 
criteria from the TargetScan database (which is able to 
significantly enrich a gene population in validated 
3’ targets [34]) and combined this with our tissue-specific 
gene and miRNA expression data (Figure S1 in Additional 
file 1). Evaluation of the ranking procedure was carried 
out through the identification of statistically enriched 
and biologically validated gene ontologies and canonical 
signaling pathways, following adjustment for multiple 
comparison testing, in the most targeted compared with 
the least targeted genes. Such an approach was viable 
using the TargetScan database as we require the context 
scoring metric as an input for the weighted cumulative 
context ranking score (wCCS) procedure. An R-script is 
included (Additional file 2).
Present-marginal-absent call filtering is able to identify, 
with reasonable sensitivity [42], which mRNAs are 
expressed in muscle. This list of approximately 20,000 
probe sets was cross-referenced with the TargetScan 
database of miRNA target genes for the 62 T2D miRNAs 
(approximately 9,000 genes), identifying a total of approxi-
mately 4,700 muscle expressed genes with conserved 
miRNA targets sites for the diabetes-modulated miRNAs. 
Each target site, on each gene, has a distinct context score 
relating to the likelihood that a given miRNA will inhibit 
protein translation or cause mRNA cleavage [25]. 
Summation of these scores provided us with a range of 
gene-specific cumulative context scores (CCS) with a 
distribution shown in Figure S5A in Additional file 1. 
First quartile ranked mRNAs tended to be expressed at a 
lower median intensity than fourth quartile targeted 
genes in control subjects (Figure S5B in Additional file 1), 
suggesting miRNA-mediated suppression of mRNA 
abundance or co-evolution of tissue-specific expression. 
Yet, when tested, we found no association between these 
miRNA target mRNAs and abundance across the clinical 
groups (Figure S5C,D in Additional file 1), which is in 
agreement with our Affymetrix analysis. Indeed, convinc-
ing evidence that mRNA cleavage occurs in mammalian 
cells originates from studies where very large changes in 
a single miRNA are created by transfection or knock-
down and this may not be relevant in vivo.
We further reasoned that the net effect of the up-
regulated (n = 29) and down-regulated (n = 33) miRNAs 
on a particular gene would be a product of the change in 
miRNA expression and the CCS. To model this we 
adjusted each target site context score by the diabetes 
related changes in miRNA expression to provide a wCCS. 
The upper quartile of up- and down-regulated diabetes 
miRNA targeted genes (first quartile wCCS genes) yields 
two overlapping gene lists, where approximately 270 
targets are common to both lists (Figure 3a). We summed 
the wCCS for the common 270 genes, taking direction of 
change into account, and for the majority of cases the 
wCCS for the up-regulated miRNA targets equaled the 
wCCS for the down-regulated miRNA targets (suggesting 
we should expect no net impact on protein expression, 
for example, for PTBP1). However, for approximately 
10% of overlapping genes the wCCS was sufficiently 
strong such that the gene was retained in either the first 
quartile up- or down-regulated list.
Validation of the weighted CCS ranking procedure by 
ontological and pathway analysis
Ontological analysis is complex and for analysis of these 
wCCS adjusted target lists we combined the two, non-
overlapping (Figure 3a) lists to explore the targeted bio-
logical processes. We did this using the muscle-specific 
transcriptome as the background file (use of the entire 
genome is inappropriate, as the muscle-specific trans-
criptome is already highly enriched in ontologies). Highly 
significant enrichment was uniquely found within the 
first quartile of ranked genes, including metabolic 
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Figure 3. See next page for legend.
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(P < 7.4 × 10-8), post-translational modification (P < 9.7 × 
10-5) and developmental (P < 1.3 × 10-6) processes (all 
Benjamini-Hochberg adjusted). Further analysis, using 
only the predicted target list as background (to establish 
if those genes with the highest wCCS contribute to 
unique bio logical activities beyond the ontological profile 
of the entire miRNA mRNA target list) retained tissue 
develop ment, and more specifically homeobox gene 
modulation, as a significant feature (FDR <5%). The 4th 
quartile of conserved wCCS targets did not demonstrate 
such enrichment (Additional file 2). Given that the 
mRNA trans criptome was invariant and the proposed 
bio chemistry of skeletal muscle insulin resistance, 
modula tion of post-translational and metabolic processes 
is a logical finding, while our analysis highlights muscle 
development, possibly regulation of muscle stem-cell 
status, as being of potential importance.
Ontological enrichment of a target gene-list provides 
statistical evidence of distinct biological processes being 
targeted by the miRNAs that change in human diabetes, 
but it remains a further challenge to pinpoint the signal-
ing pathways involved in the disease process from these 
alone. To this end, canonical pathway analysis was used 
(based on Ingenuity verified interactions) to visualize 
whether first quartile genes belong to known insulin 
resistance related processes. We found approximately six 
significant canonical pathways (Figure S6 in Additional 
file 1) represented within our first quartile wCCS list; 
encouragingly, these represent incompletely described 
diabetes disease pathways. The highest ranked signaling 
pathway, transforming growth factor-β signaling, is 
extensively implicated in all aspects of skeletal muscle 
function [61], while at an individual gene level, the 
directional changes in ERK1/2 and MEK1/2 are consis-
tent with the emerging mechanism through which 
saturated fatty acids induce muscle insulin resistance [62] 
and with decreased IRS-1 (insulin receptor substrate-1) 
phosphorylation [63] promoting the degradation of IRS-1 
[64] and thus impaired insulin action. Furthermore, 
modulation of glucocorticoid signaling [65-67], cAMP 
metabolism [68-70] and BDNF activity [71-75] are 
connected with insulin resistance in humans and various 
animal models. Thus, the novel tissue-specific wCCS-
based analysis of the 62 miRNAs altered in human 
diabetic muscle correctly identified diabetes-related 
disease mechanisms, providing support for this new 
method of functional annotation of in vivo global miRNA 
data sets. The fourth quartile of conserved wCCS targets 
did not demonstrate any canonical pathway enrichment 
above the level of chance. We recently produced a parallel 
miRNA and mRNA profile of adipogenesis. When 
applying the wCCS we again found ontological enrich-
ment in the first quartile versus fourth quartile ranked 
genes; >80% of the first quartile genes were not part of 
the diabetes miR target list and the ontological profile 
was distinct (data not shown).
Protein validation of the wCCS method
While the informatic validation of the ranking procedure 
was encouraging, it was important to provide evidence 
that protein abundance changes could be correctly 
predicted. As noted above, the wCCS correctly identified 
both CDC42 and PTBP1 protein abundance as un-
changed and our protein analysis confirmed this. We 
then examined the mRNA and protein expression of four 
additional developmental protein targets that were 
predicted to be up-regulated either in the skeletal muscle 
tissue (HOXA3, BCL2L11 (also known as BIM1) and 
HOXC8) or, in the case of BDNF, in the skeletal muscle 
satellite cells. These targets were selected based on there 
Figure 3. Generation and validation of a weighted cumulative context score for type 2 diabetes miRNAs. (a) Target genes with a more 
negative cumulative context score (CCS) are, on average, expressed at a lower level than non-targeted genes (Additional file 2). To determine 
which genes are most targeted when there is a shift in global miRNA expression, the distribution of CCS was adjusted on a gene by gene basis for 
the magnitude of up-/down-modulation of [miRNA] - wCCS. As can be seen, despite the vast number of potential predicted targets (Figure S5A 
in Additional file 1), few target genes have highly scoring wCCSs. There were 279 genes in the first quartile predicted to be up-regulated (reduced 
regulation by miRNAs) and 355 in the first quartile predicted to be down-regulated (increased regulation by miRNAs). The composition of these 
lists was validated using pathway and ontology analysis (b). Consistent with the global Affymetrix analysis (Figure S2 in Additional file 1) the 
mRNA of developmental related first quartile wCCS genes was identical between patients and controls. This was true regardless of whether the 
gene should be up-regulated (BDNF, BCL2L11(BIM), HOXA3, HOXC8, HOXA7 and HOXB7), down-regulated (HOXC4), or unchanged (CDC42 and 
PTBP1). This indicates miRNA are operating to block protein translation. Error bars = s.e.m. (c) Proteins highly ranked for being up-regulated were 
selected and protein expression was analyzed in skeletal muscle biopsies from normal glucose tolerant controls (NGT; n = 6) and subjects with 
T2D (DM; n = 6). From a second set of subjects, satellite cells were isolated from skeletal muscle biopsies from normal glucose tolerant controls 
(NGT) (n = 5 to 6) and subjects with T2D (DM; n = 5 to 6). The satellite cells were harvested in a proliferative state or as differentiated into myotubes. 
Protein expression was analyzed by using western blotting and specific antibodies towards the protein targets. HOXA3 (top left) was detected as 
a 30 kDa band, significantly up-regulated in muscle from subjects with T2D (P = 0.006). BCL2L11 (BIM; top middle) was detected as a band around 
25 kDa, significantly up-regulated in muscle from subjects with T2D (P = 0.014). HOXC8 (top right) was detected as a band around 36 kDa and 
demonstrated a clear trend for up-regulation (P = 0.07). BDNF (bottom) was detected as a band at 14 kDa, up-regulated in proliferating satellite 
cells derived from subjects with T2D where it is typically expressed (p = 0.014) but was not expressed in differentiated satellite cells or adult muscle. 
* = P value < 0.05; ** = P value < 0.001.
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being an available and functioning antibody, and because 
they appear near the top of the first quartile of the wCCS 
gene list. We noted that yet again there were no shifts in 
mRNA abundance of these target genes (Figure  3b). 
Convincingly, we demonstrated that HOXA3 and 
BCL2L11 proteins were up-regulated by approximately 
50%, while BDNF was also up-regulated (Figure  3c). 
HOXC8 expression was altered less markedly but there 
was a clear trend consistent with the prediction (P = 0.07). 
We also examined the Baek et al. [23] database of in vitro 
global protein changes when miRNAs were artificially 
manipulated in a HeLa cell system. Our wCCS ranking 
yielded analysis consistent with their protein level 
changes (Additional file 2). Thus, protein analysis 
supported the validity of our tissue-specific wCCS 
ranking approach for interpretation of the consequences 
of multiple in vivo miRNA changes.
Discussion
The molecular processes contributing to skeletal muscle 
insulin resistance are incompletely understood [76], 
while evidence that developmental factors may play a role 
is accumulating [77]. The present genome-wide RNA 
analysis presents further evidence that the human 
skeletal muscle coding transcriptome in T2D is indistin-
guishable from that of control subjects. In contrast, 
miRNA profiling, coupled with the wCCS analysis 
method, indicates approximately one-third of muscle-
expressed miRNAs are altered in diabetes and that 
collectively these miRNAs target established diabetes-
related signaling pathways and highlight a potential role 
for developmental genes. This included BDNF, which was 
only expressed in satellite cells and this may be disease 
specific as it has been found to be unaltered by physical 
activity status in humans or rodents [18,73]. A seventh 
protein (LIF) was validated very recently in our lab. 
However, wider protein level validation of the wCCS 
approach will require large scale sensitive proteomics, and 
this is not an easy option with small human clinical 
samples at this time. Meanwhile, targeted protein 
profiling of highly ranked proteins identified by our 
method is a viable alternative for studying miRNA 
regulated protein networks. Establishment of additional 
parallel coding and non-coding transcriptome data sets, 
where multiple miRNA families are simultaneously 
altered by disease or physiological stimuli, will provide 
opportunity to further refine the wCCS approach.
The invariant type 2 diabetes skeletal muscle mRNA 
transcriptome: experimental design considerations
A limitation of microarray technology is that it does not 
provide data on possible protein level changes. Never-
theless, if one wants to establish system-wide changes - 
on the understanding that complex phenotypes involve 
differential regulation of gene networks, not just 
individual genes - then microarrays are currently the 
systems biology tool of choice. In contrast to the 
unchanged global transcriptome in insulin resistant 
skeletal muscle, there are several observations that the 
expression of individual mRNA transcripts display 
altered expression in the skeletal muscle of patients with 
T2D on a gene-by-gene basis. However, such changes 
[78] do not correlate with disease severity and often are 
not reproducible in larger samples [79]. Using an 
appropriately matched cohort approximately ten times 
the size of the Patti et al. study [2], we establish that the 
T2D global muscle coding-RNA transcriptome is in-
variant, while our subgroup analysis, designed to be 
comparable with Mootha et al. [1], demonstrates that 
their observation of a reduced OXPHOS gene set in T2D 
patients appears to reflect the acute differential response 
to pharmacological levels of insulin [80] in their control 
subjects, or some other confounding drug treatment in 
their diabetes patients (for example, statin therapy). This 
conclusion is in agreement with recent physiological 
studies [11,81,82] where no intrinsic defect in mito-
chondrial biochemical function was found in the skeletal 
muscle of T2D subjects.
Despite this major difference in study interpretation 
and conclusion, all human microarray studies examining 
insulin resistance in skeletal muscle paint a remarkably 
similar picture - one of no striking change in protein 
coding mRNA abundance. In the Patti et al. study [2], 
muscle samples from a small group of subjects of 
Mexican-American ethnicity were studied using the 
Affymetrix HuGeneFL array platform, representing only 
15% of the RNA transcriptome, and no significant 
differences were found. A gene-by-gene qPCR approach 
was also used, yielding evidence for reduced transcrip-
tional regulators of OXPHOS gene expression [2]. 
However, as oxidative metabolism proteins can be altered 
with physical inactivity [15], and a very large difference in 
demographics existed between the groups [2], then the 
observation made probably does not reflect diabetes. 
Another problem with the study by Patti et al. [2] was 
that patients were taken off their medication only 
48  hours prior to obtaining the muscle biopsy. In the 
present study we ensured patients with T2D ceased 
taking their hypoglycemic medication for 1 week prior to 
clinical measurements and muscle biopsy. Interestingly, 
short-term and long-term measures of glucose control - 
fasting glucose and HbA1c - remained highly correlated 
(R2  =  0.71) in our study, suggesting that after being 
treated for a number of years, drug therapy was no longer 
providing a substantial influence on hyperglycemia [83]. 
This discussion highlights the possibility that protein 
signaling changes previously ascribed to the insulin 
resistance disease process [84] may in fact be a refractory 
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response to pharmaceutical medication and hence 
represent an artifact of study design.
Mootha et al. [1] studied a group of older diabetes 
subjects (approximately 66 years) using a microarray 
platform that provides greater coverage of the trans-
criptome (approximately 20,000 sequences). The authors 
applied a now robust statistical approach [54] and 
presented evidence that there was a statistically signifi-
cant down-regulation of a group of genes involved in 
oxidative metabolism (OXPHOS) in skeletal muscle of 
T2D subjects, and claimed that this ‘gene set’ reflected 
reduced PGC-1α activity. In the present, much larger 
analysis we did not identify any correlation between 
glucose or insulin levels and any gene set including 
OXPHOS or PGC-1α. To examine the discrepancy 
between our data set and the Mootha et al. study [1], we 
ran GSEA on a subgroup of our patients that closely 
approximated the demographics of their study. Hence, 
the only difference between the two studies should be the 
3-hour hyperinsulinemia exposure prior to biopsy 
sampling in the Mootha et al. study. In our subjects, the 
OXPHOS gene set was ranked the least enriched gene set 
in the NGT subjects, supporting the idea that obtaining 
the biopsy samples after a period of pharmacological 
hyperinsulinemia created an acute change in OXPHOS 
genes as T2D patients will respond differently to pharma-
cological levels of insulin infusion compared to control 
subjects [3]. Thus, although substantial loss of 
mitochondrial function can cause metabolic dysfunction 
and muscle insulin resistance or diabetes [5], this is not 
synonymous with evidence that OXPHOS defects are a 
causal or primary defect in T2D and we cannot demon-
strate that such a defect exists in the skeletal muscle of 
diabetes patients. Further, the major deter minants of 
skeletal muscle mitochondrial status - physical activity 
and physical fitness [85] - were not controlled for in any 
study and thus the OXPHOS-diabetes disease association 
should be considered unreliable.
Coordinated alteration in human skeletal muscle miRNA 
expression relates to insulin resistance in type 2 diabetes
We provide new evidence that disrupted miRNA 
expression may have relevance for insulin resistant 
skeletal muscle. Firstly, one-third of miRNAs robustly 
expressed in muscle (62 out of 171) have altered 
expression in diabetes patients and a subset of these is 
altered early in disease where patients remain untreated 
(Figure  2a). Secondly, we demonstrate that the highest 
ranked wCCS genes belonged to relevant biochemical 
processes, namely post-translational modification and 
metabolic pathways. Further, the genes ranked as being 
targeted most strongly by the collective net changes in 
miRNA expression target approximately six significant 
canonical signaling pathways, five of which are described 
as related to insulin resistance or muscle metabolism [65-
75]. This level of statistical evidence is robust, especially 
when one considers the fourth quartile ranked genes 
demonstrated no such associations.
Several miRNAs are highly regulated in vivo and in 
vitro during muscle development and these regulate the 
muscle differential expression process [55]. Most studied 
are miR-133, miR-206 and miR-1, which are all induced 
during differentiation of myoblasts into myotubes [28]. 
We were able to demonstrate using a separate detection 
system that altered myomir expression varies with 
disease severity and that gene-chip expression of a sub-
group of miRNAs (10 out of 11) was regulated in a 
manner diametrically opposite that observed during 
muscle differentiation. Over-expression of miR-1 [55] or 
miR-206 [86] in mouse myoblasts accelerates differen-
tiation into myotubes whereas over-expression of 
miR-133 promotes proliferation [55]. In vivo the expres-
sion of these miRNAs can vary as miR-1 and miR-133a 
decrease 50% in response to muscle hypertrophy in mice 
following 7 days of loading [87]. As discussed below, and 
implicit in the successful identification of diabetes disease 
processes using the wCCS ranking approach and in vivo 
miRNA profiling, it is the combinatorial nature of miRNA 
action in vivo that seems to be most relevant. To this end 
we have been able to call the protein expression 
differences correctly (seven from seven) between controls 
and TD2 subjects using the wCCS ranking approach, and 
in doing so expand the evidence base for the involvement 
of developmental genes in muscle insulin resistance. 
These observations indicate that we have made progress 
in addressing a major challenge in the miRNA field, 
namely that of interpretation of biological consequences 
of in vivo multiple miRNA modulation [23].
Using the myomir family as an example, we attempted 
to establish why we observed changes in mature miRNA 
abundance. Current understanding of miRNA biogenesis 
and processing is primarily based on in vitro and genetic 
studies in lower organisms [88]. Mature miRNAs are 
derived from a longer primary transcript - approximately 
1 to 3 kb transcribed by RNA polymerase II [89] - that 
are then processed in the nucleus by Drosha to form an 
approximately 70- to 80-nucleotide precursor miRNA 
[90]. This pre-miRNA is exported to the cytoplasm via 
Exportin 5 [91] where Dicer cleaves the pre-miRNA to 
leave a 20- to 22-nucleotide mature miRNA that is 
incorporated into a waiting RISC complex, where it can 
bind complementary target mRNAs and suppress 
translation of multiple mRNAs. Many miRNAs are trans-
cribed as a ‘cluster’ from a single genomic region and it 
has been stated that for the myomirs, each should be co-
transcribed and co-expressed. However, evidence of 
distinct binding proteins that modulate processing of 
pri-miRNA to mature miRNA [92] has emerged and we 
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clearly demonstrate that expression of miR-1 and 
miR-133a are not co-regulated in vivo in human skeletal 
muscle. This suggests that either processing of the 
pri-miR-133a or stability of mature miR-133a is altered in 
T2D. Regulation of miRNA production, post-trans-
criptionally, is proving to be potentially important for 
determining stem cell differentiation [93,94] while the 
protein or signaling factors that inhibit miR-133a produc-
tion in T2D remain to be determined, this process clearly 
has the potential to alter muscle differentiation [28].
Human skeletal muscle insulin resistance and 
developmental genes
Given the chronic nature of skeletal muscle insulin 
resistance in diabetes and the role of satellite cells in 
maintaining long-term physiological function [95], it is 
surprising that so little is known about muscle stem cell 
status in T2D. So we were particularly interested in the 
idea that satellite cell function may be altered in TD2 
[73]. Our analysis indicated that modulated miRNAs 
collectively target developmental processes (P < 1.3 × 10-6) 
and thus we speculate that at least part of the disease 
process occurs within the skeletal muscle stem cells 
(satellite cells). Disrupted muscle repair would be 
consistent with the involvement of BDNF expression 
inhibiting myogenesis [96] and we demonstrated that 
BDNF is elevated in proliferating satellite cells from diabetes 
patients (Figure 3c). Interestingly, BDNF mRNA expression 
is not altered by endurance training [18] and additional RT-
qPCR on this material (n = 24, data not shown) found it 
barely detectable in adult muscle tissue. Indeed, BDNF was 
only reliably detectable in activated muscle satellite cells. 
Studies on muscle damage in chemically induced diabetes 
models show impaired recovery [73], while this interesting 
link between diabetes, BDNF and muscle recovery remains 
to be studied in humans.
In support of our focus on developmental genes, 
pathway analysis of recent genome-wide association 
studies, which so far have yielded few T2D candidate 
genes, provided an integrated interpretation of the 
highest ranked risk genes for T2D [97]. This analysis 
found that lipid metabolism and developmental genes 
were significantly over-represented in the upper ranked 
genes of the T2D genome-wide association studies, an 
observation based on thousands of samples, and one 
strongly consistent with the present independent 
analysis. Combined, we believe this presents strong 
evidence that developmental genes may play a role in 
setting or regulating the long-term responses of skeletal 
muscle to diabetes.
Conclusions
In the present analysis, we provide robust evidence 
that combining multiple single-gene predictions 
produced a set of targets that could be validated at 
several levels. Indeed, we have so far found the method 
to be 100% accurate. However, there are a number of 
additional theoretical considerations that need to be 
mentioned, as the wCCS method currently does not 
include potentially important information. Firstly, we 
did not integrate the target site multiplicative effect 
[33] due to a lack of information on the synergy 
between the proximity of hetero geneous miRNA target 
sites and protein trans lational block. Thus, as lower 
ranked protein targets are considered, the precision of 
the method may decline. Nor did we integrate absolute 
miRNA abundance data. Thus, we did not distinguish 
between changes in high abun dance and low 
abundance miRNAs. The main reason for this 
omission is that we can not accurately compare 
miRNA abundance across probes on a microarray, as 
each probe produces linear detection of single miRNA 
abundance and the signal is not designed to be 
compared across detection probes. Nevertheless, given 
the enor mous range of probe intensities, it is likely 
that some changes do represent much larger absolute 
alterations in miRNA concentration than others. Thus, 
it may be possible to further refine the interpretation 
of coordi nated in vivo changes in miRNA expression if 
we adjust the wCCS score by miRNA absolute 
concentration. One needs to do this with some caution 
as the precise ‘potency’ of a given miRNA, as well as 
subcellular compart mentalization, ensures that such a 
calculation is unlikely to be a simple linear one.
The new ranking strategy detects relevant biology 
without bias relating to protein isolation or chemistry 
and thus can aid pathway mining where clinical biopsy 
size prevents global proteomics. The present analysis 
indicates that collective miRNA changes in vivo should 
be taken into account. Technically, it would be 
challenging to mimic this in cells as the simultaneous 
knock-down of 33 miRNA combined with over-expres-
sion of 29 up-regulated miRNAs, all at the correct 
dosage, is intractable and would be of questionable 
physio logical relevance in a cell culture system. In 
conclusion, we provide the first global RNA profile of 
human skeletal muscle insulin resistance and demon-
strate a remarkably invariant mRNA landscape. We 
present a new method for interpretation of multiple 
miRNA changes in vivo, analysis that extends the 
evidence that developmental genes play a role in 
metabolic disease [97,98]. miRNAs can be robustly 
detected in minute amounts of RNA, collected by pain-
free micro-needle sampling, such that we believe they 
represent plausible biomarkers of muscle status, and 
may be useful for monitoring pharmacodynamics and 
early-stage efficacy during larger-scale diabetes 
intervention trials.
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